{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:35:24Z","timestamp":1790620524226,"version":"4.1.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:00:00Z","timestamp":1644537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The aim of this study was to describe clinical features in different subtypes of chronic pulmonary aspergillosis (CPA)-simple aspergilloma (SA), chronic cavitary pulmonary aspergillosis (CCPA), chronic fibrosing pulmonary aspergillosis (CFPA), aspergillus nodule (AN), and subacute invasive aspergillosis (SAIA), respectively, and identify long-term prognosis of CPA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We reviewed patients diagnosed with different subtypes of CPA from 2002 to 2020 at Nanjing Jinling Hospital, China. We analyzed the clinical and survival information of five different subgroups. A Cox regression model was used to explore proper antifungal duration and long-term survival factors of CCPA and SAIA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 147 patients with CPA were included, consisting of 11 SA, 48 CCPA, 5 CFPA, 12 AN, and 71 SAIA. The most common underlying pulmonary disease was pulmonary tuberculosis (<jats:italic>n<\/jats:italic> = 49, 33%), followed by bronchiectasis (<jats:italic>n<\/jats:italic> = 46, 31.3%) and chronic obstructive pulmonary disease (COPD) or emphysema (<jats:italic>n<\/jats:italic> = 45, 30.6%), while in SAIA and CFPA groups, the most common was COPD or emphysema (45.1 and 100%). Cough (85%), expectoration (70.7%), hemoptysis (54.4%), and fever (29.9%) were common symptoms, especially in CCPA, CFPA, and SAIA groups. The common imaging manifestations included cavitation (<jats:italic>n<\/jats:italic> = 94, 63.9%), fungal ball (<jats:italic>n<\/jats:italic> = 54, 36.7%), pleural thickening (<jats:italic>n<\/jats:italic> = 47, 32.0%), and bronchiectasis (<jats:italic>n<\/jats:italic> = 46, 31.3%). SAIA and CFPA groups had a lower value of hemoglobin (HB) and serum albumin (ALB) with higher C-reactive protein and erythrocyte sedimentation rate. The positive rate of sputum culture, serum galactomannan (GM), and bronchoalveolar lavage fluid GM was 32.7% (36\/110), 18.4% (18\/98), and 48.7% (19\/39), respectively. There were 64.6% (31\/48) patients with CCPA and 25.4% (18\/71) patients with SAIA who received surgery and the 5-year cumulative survival rate was 92.1 and 66.6%, respectively. SAIA, old age, male, low body mass index (BMI), COPD or emphysema, multiple distribution, low serum ALB, and positive sputum culture were adverse prognosis factors for SAIA and CCPA group, and BMI \u2264 20.0 kg\/m<jats:sup>2<\/jats:sup> was independently associated with increased mortality (hazard ratio (<jats:italic>HR<\/jats:italic>) 5.311, 95% <jats:italic>CI<\/jats:italic> 1.405\u201320.068, <jats:italic>p<\/jats:italic> = 0.014). Multivariable Cox regression indicated that surgery (<jats:italic>HR<\/jats:italic> 0.093, 95% <jats:italic>CI<\/jats:italic> 0.011\u20130.814, <jats:italic>p<\/jats:italic> = 0.032) and antifungal duration &amp;gt;6 months (<jats:italic>HR<\/jats:italic> 0.204, 95% <jats:italic>CI<\/jats:italic> 0.060\u20130.696 <jats:italic>p<\/jats:italic> = 0.011) were related to improved survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The clinical features and laboratory test performance are different among SA, CCPA, CFPA, AN, and SAIA. Low BMI was an independent risk factor for survival. Selective surgery and antifungal duration over 6 months were associated with improved survival.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.811807","type":"journal-article","created":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T05:31:42Z","timestamp":1644557502000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Clinical Features, Diagnostic Test Performance, and Prognosis in Different Subtypes of Chronic Pulmonary Aspergillosis"],"prefix":"10.3389","volume":"9","author":[{"given":"Huanhuan","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaru","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyan","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunlu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"165rv13","DOI":"10.1126\/scitranslmed.3004404","article-title":"Hidden killers: human fungal infections","volume":"4","author":"Brown","year":"2012","journal-title":"Sci Transl Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e00140","DOI":"10.1128\/CMR.00140-18","article-title":"Aspergillus fumigatus and aspergillosis in 2019","volume":"33","author":"Latge","year":"2019","journal-title":"Clin Microbiol Rev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1183\/09031936.00054810","article-title":"Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma","volume":"37","author":"Smith","year":"2011","journal-title":"Eur Respir J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1183\/13993003.00583-2015","article-title":"Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management","volume":"47","author":"Denning","year":"2016","journal-title":"Eur Respir J."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e8315","DOI":"10.1097\/MD.0000000000008315","article-title":"Clinical features and diagnosis of chronic pulmonary aspergillosis in Chinese patients","volume":"96","author":"Hou","year":"2017","journal-title":"Medicine."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e0249455","DOI":"10.1371\/journal.pone.0249455","article-title":"Prognostic factors of chronic pulmonary aspergillosis: a retrospective cohort of 264 patients from Japan","volume":"16","author":"Kimura","year":"2021","journal-title":"PLoS ONE."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1601062","DOI":"10.1183\/13993003.01062-2016","article-title":"Predictors of mortality in chronic pulmonary aspergillosis","volume":"49","author":"Lowes","year":"2017","journal-title":"Eur Respir J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2003345","DOI":"10.1183\/13993003.03345-2020","article-title":"Chronic pulmonary aspergillosis: prevalence, favouring pulmonary diseases and prognosis","volume":"58","author":"Maitre","year":"2021","journal-title":"Eur Respir J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1801184","DOI":"10.1183\/13993003.01184-2018","article-title":"Chronic pulmonary aspergillosis commonly complicates treated pulmonary tuberculosis with residual cavitation","volume":"53","author":"Page","year":"2019","journal-title":"Eur Respir J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"101041","DOI":"10.1016\/j.mycmed.2020.101041","article-title":"Clinical features and outcome of patients with chronic pulmonary aspergillosis in China: a retrospective, observational study","volume":"30","author":"Niu","year":"2020","journal-title":"J Mycol Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.rmed.2012.01.014","article-title":"Clinical characteristics and prognosis of chronic pulmonary aspergillosis","volume":"106","author":"Ohba","year":"2012","journal-title":"Respir Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e0193732","DOI":"10.1371\/journal.pone.0193732","article-title":"Twelve-month clinical outcomes of 206 patients with chronic pulmonary aspergillosis","volume":"13","author":"Bongomin","year":"2018","journal-title":"PLoS ONE."},{"key":"B13","doi-asserted-by":"publisher","first-page":"jiab583","DOI":"10.1093\/infdis\/jiab583","article-title":"Defective interferon-gamma production is common in chronic pulmonary aspergillosis","author":"Colombo","year":"2021","journal-title":"J Infect Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1183\/09031936.06.00021705","article-title":"Interferon-gamma therapy in two patients with progressive chronic pulmonary aspergillosis","volume":"27","author":"Kelleher","year":"2006","journal-title":"Eur Respir J."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1900117","DOI":"10.1183\/13993003.00117-2019","article-title":"Nontuberculous mycobacterial pulmonary disease and Aspergillus co-infection: Bonnie and Clyde?","volume":"54","author":"Geurts","year":"2019","journal-title":"Eur Respir J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/cid\/ciw444","article-title":"Executive summary: practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/jac\/dkx390","article-title":"A CPAnet consensus statement on research priorities for chronic pulmonary aspergillosis: a neglected fungal infection that requires attention","volume":"73","author":"Godet","year":"2018","journal-title":"J Antimicrob Chemother."},{"key":"B18","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12890-016-0276-3","article-title":"Aspergillus nodules; another presentation of chronic pulmonary aspergillosis","volume":"16","author":"Muldoon","year":"2016","journal-title":"BMC Pulm Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jiac.2013.10.016","article-title":"Pathogenesis and clinical features of chronic pulmonary aspergillosis - is it possible to distinguish CNPA and CCPA clinically?","volume":"20","author":"Izumikawa","year":"2014","journal-title":"J Infect Chemother."},{"key":"B20","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3109\/13693786.2013.806826","article-title":"Clinical characteristics and treatment outcomes of chronic pulmonary aspergillosis","volume":"51","author":"Jhun","year":"2013","journal-title":"Med Mycol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/crj.12105","article-title":"Characteristics and outcomes of chronic pulmonary aspergillosis: a retrospective analysis of a tertiary hospital registry","volume":"9","author":"Camara","year":"2015","journal-title":"Clin Respir J."},{"key":"B22","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1093\/cid\/cit411","article-title":"Long-term antifungal treatment improves health status in patients with chronic pulmonary aspergillosis: a longitudinal analysis","volume":"57","author":"Al-Shair","year":"2013","journal-title":"Clin Infect Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1164\/rccm.201410-1876PP","article-title":"Blue journal conference. Aging and susceptibility to lung disease","volume":"191","author":"Thannickal","year":"2015","journal-title":"Am J Respir Crit Care Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1097\/QAD.0b013e32833a2a4a","article-title":"Body mass index and risk of tuberculosis and death","volume":"24","author":"Hanrahan","year":"2010","journal-title":"AIDS."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e392","DOI":"10.1093\/cid\/ciaa054","article-title":"Impact of diabetes and low body mass index on tuberculosis treatment outcomes","volume":"71","author":"Kornfeld","year":"2020","journal-title":"Clin Infect Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/NEJMoa021322","article-title":"The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease","volume":"350","author":"Celli","year":"2004","journal-title":"N Engl J Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"6782","DOI":"10.1128\/AAC.03641-14","article-title":"Impact of hypoalbuminemia on voriconazole pharmacokinetics in critically ill adult patients","volume":"58","author":"Vanstraelen","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.rmed.2013.04.007","article-title":"The utility of galactomannan antigen in the bronchial washing and serum for diagnosing pulmonary aspergillosis","volume":"107","author":"Kono","year":"2013","journal-title":"Respir Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e01821","DOI":"10.1128\/JCM.01821-18","article-title":"Utility of serum and bronchoalveolar lavage fluid galactomannan in diagnosis of chronic pulmonary aspergillosis","volume":"57","author":"Sehgal","year":"2019","journal-title":"J Clin Microbiol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3109\/13693786.2012.682228","article-title":"Bronchoalveolar lavage galactomannan for the diagnosis of chronic pulmonary aspergillosis","volume":"50","author":"Izumikawa","year":"2012","journal-title":"Med Mycol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.3389\/fmicb.2019.01438","article-title":"Role of the aspergillus-specific IgG and IgM test in the diagnosis and follow-up of chronic pulmonary aspergillosis","volume":"10","author":"Li","year":"2019","journal-title":"Front Microbiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"115124","DOI":"10.1016\/j.diagmicrobio.2020.115124","article-title":"Evaluation and comparison of automated and manual ELISA for diagnosis of chronic pulmonary aspergillosis (CPA) in Indonesia","volume":"98","author":"Setianingrum","year":"2020","journal-title":"Diagn Microbiol Infect Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1186\/s12879-019-4303-x","article-title":"Prospective study of the serum aspergillus-specific IgG, IgA and IgM assays for chronic pulmonary aspergillosis diagnosis","volume":"19","author":"Ma","year":"2019","journal-title":"BMC Infect Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jinf.2015.11.003","article-title":"Comparison of six aspergillus-specific IgG assays for the diagnosis of chronic pulmonary aspergillosis (CPA)","volume":"72","author":"Page","year":"2016","journal-title":"J Infect."},{"key":"B36","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.athoracsur.2013.10.050","article-title":"Surgical therapy of pulmonary aspergillomas: a 30-year North American experience","volume":"97","author":"Muniappan","year":"2014","journal-title":"Ann Thorac Surg."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1016\/j.jss.2010.06.039","article-title":"Predictive and prognostic value of preoperative symptoms in the surgical treatment of pulmonary aspergilloma","volume":"163","author":"Sagan","year":"2010","journal-title":"J Surg Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s40265-019-01127-8","article-title":"Adverse effects associated with long-term administration of azole antifungal agents","volume":"79","author":"Benitez","year":"2019","journal-title":"Drugs."},{"key":"B39","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/1749-8090-8-180","article-title":"Results of surgery for chronic pulmonary aspergillosis, optimal antifungal therapy and proposed high risk factors for recurrence\u2013a National Centre's experience","volume":"8","author":"Farid","year":"2013","journal-title":"J Cardiothorac Surg."},{"key":"B40","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1136\/thx.38.8.572","article-title":"Pulmonary aspergilloma: analysis of prognosis in relation to haemoptysis and survey of treatment","volume":"38","author":"Jewkes","year":"1983","journal-title":"Thorax."},{"key":"B41","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/ejcts\/ezaa137","article-title":"Clinical outcomes of patients with chronic pulmonary aspergillosis managed surgically","volume":"58","author":"Setianingrum","year":"2020","journal-title":"Eur J Cardiothorac Surg."},{"key":"B42","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.jinf.2021.07.030","article-title":"Impact of treatment duration on recurrence of chronic pulmonary aspergillosis","volume":"83","author":"Im","year":"2021","journal-title":"J Infect."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.811807\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T05:31:45Z","timestamp":1644557505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.811807\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,11]]},"references-count":42,"alternative-id":["10.3389\/fmed.2022.811807"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.811807","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,11]]},"article-number":"811807"}}